Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Cassava Sciences Inc
(NQ:
SAVA
)
23.12
+1.56 (+7.24%)
Streaming Delayed Price
Updated: 4:00 PM EDT, May 17, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Cassava Sciences Inc
< Previous
1
2
3
4
5
6
7
8
9
...
30
31
Next >
Cassava Sciences Announces Science Publication That Confirms Mechanism of Action of Simufilam, a Novel Drug Candidate for People with Alzheimer’s Disease
September 11, 2023
From
Cassava Sciences, Inc.
Via
GlobeNewswire
Cassava Sciences Invited to Present in Four Upcoming Investor Conferences
September 06, 2023
From
Cassava Sciences, Inc.
Via
GlobeNewswire
Snowflake (SNOW) Stock Is Sliding Despite AI Hopes
August 24, 2023
Snowflake (SNOW) stock is on the move Thursday following the release of the company's second-quarter earnings report for fiscal 2024.
Via
InvestorPlace
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
Is Splunk (SPLK) Stock the Next AI Giant?
August 24, 2023
Splunk (SPLK) stock climbed higher on Thursday as investors weighed the company's value in the AI market following its earnings report.
Via
InvestorPlace
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
Why Cassava Sciences Stock Is Trading Down Today
July 05, 2023
Cassava Sciences, Inc. (NASDAQ: SAVA) shares are trading lower Wednesday.
Via
Benzinga
Why Shares of Cassava Sciences Are Dropping Wednesday
July 05, 2023
The company announced phase 3 trial results for its lead Alzheimer's therapy.
Via
The Motley Fool
Why Shares of Cassava Sciences Jumped This Week
May 12, 2023
Cassava Sciences finished dosing in one of its phase 3 trials for its Alzheimer's therapy Simufilam.
Via
The Motley Fool
Insider Richard Barry Just Doubled Down on Cassava (SAVA) Stock
August 24, 2023
Cassava had $168.4 million of cash at the end of June after losing $28.7 million during the second quarter of 2023. SAVA stock is up 5%
Via
InvestorPlace
10 Health Care Stocks With Whale Alerts In Today's Session
August 14, 2023
Via
Benzinga
Stocks That Hit 52-Week Lows On Friday
August 11, 2023
During the Friday's sesion, 157 stocks hit new 52-week lows.
Via
Benzinga
Cassava Sciences Reports Q2 2023 Financial Results and Operating Updates
August 03, 2023
From
Cassava Sciences, Inc.
Via
GlobeNewswire
Why These 3 Stocks Are the Worst Ways to Play Biotech Right Now
July 13, 2023
These three worst biotech stocks are not investable even if you're bullish on the sector overall. There are better options.
Via
InvestorPlace
7 Biotech Stocks to Sell in July
July 13, 2023
Running the gamut from large to small, and from commercial stage to clinical stage, these are seven top biotech stocks to sell in July.
Via
InvestorPlace
FDA Approves Biogen's Alzheimer's Drug: Here Are Other Companies With Treatments In The Pipeline
July 07, 2023
The FDA fully approved Biogen Inc.’s (NASDAQ: BIIB) Alzheimer’s treatment Leqembi on Thursday, becoming the first Alzheimer’s antibody treatment to reach full approval.
Via
Benzinga
Stock Market Round-Up: Rivian Rides High, Meta Platforms Makes Moves, And Tesla Ticks Up
July 05, 2023
Via
Benzinga
Cassava Sciences (SAVA) Stock Drops Despite Positive Trial Results
July 05, 2023
Cassava Sciences (SAVA) stock is down 11% on underwhelming results from its Phase 3 clinical trials for its Alzheimer's treatment.
Via
InvestorPlace
12 Health Care Stocks Moving In Wednesday's Intraday Session
July 05, 2023
Via
Benzinga
Dow, S&P 500 Move Lower On Renewed Fed Fatigue
July 05, 2023
Stocks are moving lower ahead of the Federal Reserve's June meeting minutes, which are due out this afternoon.
Via
Talk Markets
Promising Alzheimer's Treatment: Cassava Sciences' Simufilam Slows Cognitive Decline by 38% in Clinical Study
July 05, 2023
Cassava Sciences Inc (NASDAQ: SAVA) announced topline clinical results from its Cognition Maintenance Study (CMS), a small proof-of-concept study designed to demonstrate the effects of simufilam versus...
Via
Benzinga
Why 1847 Holdings Shares Are Trading Lower By Around 31%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
July 05, 2023
Gainers Allarity Therapeutics, Inc. (NASDAQ: ALLR) shares surged 87% to $11.78 after the company said the initial data from Phase 2 trial of Ixempra shows potential for improved clinical benefit in...
Via
Benzinga
Oral Simufilam Slowed Cognitive Decline in a Randomized Withdrawal Trial of Mild-to-Moderate Alzheimer’s Disease
July 05, 2023
From
Cassava Sciences, Inc.
Via
GlobeNewswire
New Research Shows Simufilam Suppresses Overactive mTOR
June 27, 2023
From
Cassava Sciences, Inc.
Via
GlobeNewswire
New Publication Highlights Basic Science Supporting Simufilam
June 12, 2023
From
Cassava Sciences, Inc.
Via
GlobeNewswire
Cassava Sciences to Present at the Jefferies Global Healthcare Conference
June 01, 2023
From
Cassava Sciences, Inc.
Via
GlobeNewswire
3 Biotech Stocks to Avoid Like the Plague
May 23, 2023
Investors are looking for bargains in the biotech sector. But these three biotech stocks should be avoided at all costs.
Via
InvestorPlace
10 Health Care Stocks Whale Activity In Today's Session
May 22, 2023
Via
Benzinga
Hero or Zero? 7 High-Risk Stocks to Make You Rich… Or Broke.
May 21, 2023
These seven high-risk stocks could ultimately rocket to the moon, or fall to the depths of the stock market graveyard.
Via
InvestorPlace
10 Health Care Stocks With Whale Alerts In Today's Session
May 18, 2023
Via
Benzinga
Cassava Sciences Completes Patient Dosing in a Randomized Controlled Trial of Simufilam in Alzheimer’s Disease
May 11, 2023
From
Cassava Sciences, Inc.
Via
GlobeNewswire
Top 5 Health Care Stocks That May Collapse In Q2
May 10, 2023
The most overbought stocks in the health care sector presents an opportunity to go short on these overvalued companies.
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
...
30
31
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.